https://wiki.tiffa.net/w/index.php?action=history&feed=atom&title=Talk%3AImmunoglobulin_therapy 2026-04-19T23:14:15Z Revision history for this page on the wiki MediaWiki 1.43.0 https://wiki.tiffa.net/w/index.php?title=Talk:Immunoglobulin_therapy&diff=3091&oldid=prev 2023-01-03T08:04:27Z

<p>Created page with &quot;{{Infobox drug | drug_name = | INN = | type = &lt;!-- empty --&gt; | image = | width = | alt = | caption = &lt;!-- Clinical data --&gt; | pronounce = | tradename = Flebogamma, Gammagard, Hizentra, others | Drugs.com = {{Drugs.com|monograph|immune-globulin}} | MedlinePlus = | licence_CA = &lt;!-- Health Canada may use generic or brand name (generic name preferred) --&gt;...&quot;</p> <p><b>New page</b></p><div>{{Infobox drug<br /> | drug_name =<br /> | INN =<br /> | type = &lt;!-- empty --&gt;<br /> | image =<br /> | width =<br /> | alt =<br /> | caption =<br /> <br /> &lt;!-- Clinical data --&gt;<br /> | pronounce =<br /> | tradename = Flebogamma, Gammagard, Hizentra, others<br /> | Drugs.com = {{Drugs.com|monograph|immune-globulin}}<br /> | MedlinePlus =<br /> | licence_CA = &lt;!-- Health Canada may use generic or brand name (generic name preferred) --&gt;<br /> | licence_EU = &lt;!-- EMA uses INN (or special INN_EMA) --&gt;<br /> | DailyMedID = Immune_globulin<br /> | licence_US = &lt;!-- FDA may use generic or brand name (generic name preferred) --&gt;<br /> | pregnancy_AU = Exempt<br /> | pregnancy_AU_comment = &lt;ref name=&quot;Xembify APMDS&quot; /&gt;<br /> | pregnancy_category=<br /> | routes_of_administration = [[Intravenous therapy|Intravenous]], [[Intramuscular injection|intramuscular]], [[Subcutaneous injection|subcutaneous]]<br /> | class =<br /> | ATCvet =<br /> | ATC_prefix = J06<br /> | ATC_suffix = BA<br /> | ATC_supplemental =<br /> <br /> &lt;!-- Legal status --&gt;<br /> | legal_AU = S4<br /> | legal_AU_comment = &lt;ref name=&quot;Xembify APMDS&quot;&gt;{{cite web | title=Xembify APMDS | website=[[Therapeutic Goods Administration]] (TGA) | date=15 July 2022 | url=https://www.tga.gov.au/resources/auspmd/xembify | access-date=17 July 2022 | archive-date=14 July 2022 | archive-url=https://web.archive.org/web/20220714222420/https://www.tga.gov.au/apm-summary/xembify | url-status=live }}&lt;/ref&gt;<br /> | legal_BR = &lt;!-- OTC, A1, A2, A3, B1, B2, C1, C2, C3, C4, C5, D1, D2, E, F--&gt;<br /> | legal_BR_comment =<br /> | legal_CA = Rx-only<br /> | legal_CA_comment = &lt;ref&gt;{{cite web | title=Regulatory Decision Summary - Xembify | website=Health Canada | date=23 October 2014 | url=https://hpr-rps.hres.ca/reg-content/regulatory-decision-summary-detail.php?lang=en&amp;linkID=RDS00596 | access-date=7 June 2022 | archive-date=7 June 2022 | archive-url=https://web.archive.org/web/20220607034842/https://hpr-rps.hres.ca/reg-content/regulatory-decision-summary-detail.php?lang=en&amp;linkID=RDS00596 | url-status=live }}&lt;/ref&gt;&lt;ref&gt;{{cite web | title=Summary Basis of Decision - HyQvia | website=Health Canada | date=23 October 2014 | url=https://hpr-rps.hres.ca/reg-content/summary-basis-decision-detailTwo.php?linkID=SBD00592&amp;lang=en | access-date=6 August 2022}}&lt;/ref&gt;<br /> | legal_DE = &lt;!-- Anlage I, II, III or Unscheduled--&gt;<br /> | legal_DE_comment =<br /> | legal_NZ = &lt;!-- Class A, B, C --&gt;<br /> | legal_NZ_comment =<br /> | legal_UK = &lt;!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM / Class A, B, C --&gt;<br /> | legal_UK_comment =<br /> | legal_US = Rx-only<br /> | legal_US_comment =<br /> | legal_EU = Rx-only<br /> | legal_EU_comment =<br /> | legal_UN = &lt;!-- N I, II, III, IV / P I, II, III, IV--&gt;<br /> | legal_UN_comment =<br /> | legal_status = Rx-only<br /> <br /> &lt;!-- Pharmacokinetic data --&gt;<br /> | bioavailability =<br /> | protein_bound =<br /> | metabolism =<br /> | metabolites =<br /> | onset =<br /> | elimination_half-life =<br /> | duration_of_action =<br /> | excretion =<br /> <br /> &lt;!-- Identifiers --&gt;<br /> | CAS_number_Ref = {{cascite|correct|CAS}}<br /> | CAS_number = 9007-83-4<br /> | CAS_supplemental =<br /> | PubChem =<br /> | IUPHAR_ligand =<br /> | DrugBank_Ref =<br /> | DrugBank =<br /> | ChemSpiderID_Ref =<br /> | ChemSpiderID = none<br /> | UNII_Ref = {{fdacite|correct|FDA}}<br /> | UNII = 66Y330CJHS<br /> | KEGG_Ref =<br /> | KEGG =<br /> | ChEBI_Ref =<br /> | ChEBI =<br /> | ChEMBL_Ref =<br /> | ChEMBL =<br /> | NIAID_ChemDB =<br /> | PDB_ligand =<br /> | synonyms = normal human immunoglobulin (HNIG), human normal immunoglobulin (HNIG)<br /> <br /> &lt;!-- Chemical and physical data --&gt;<br /> | IUPAC_name =<br /> | chemical_formula =<br /> | C= | H= | Ag= | Al= | As= | Au= | B= | Bi= | Br= | Ca= | Cl= | Co= | F= | Fe= | Gd= | I=<br /> | K= | Li= | Mg= | Mn= | N= | Na= | O= | P= | Pt= | S= | Sb= | Se= | Sr= | Tc= | Zn= | charge=<br /> | molecular_weight =<br /> | SMILES =<br /> | StdInChI =<br /> | StdInChI_comment =<br /> | StdInChIKey =<br /> | density =<br /> | density_notes =<br /> | melting_point =<br /> | melting_high =<br /> | melting_notes =<br /> | boiling_point =<br /> | boiling_notes =<br /> | solubility =<br /> | sol_units =<br /> | specific_rotation =<br /> }}</div>

imported>Fire